Ardena debuts new nanomedicines facility at CPHI 2024
The company explains attendees will gain insight into how Ardena’s innovations can streamline drug development for advanced therapies, particularly in oncology and specialized therapeutic areas. OSP spoke to Jeremie Trochu, CEO at Ardena in the build-up to the show.
What new products or innovations is your company showcasing at CPHI Milan this year?
Ardena will spotlight several advancements. Key among these is our new €20M state of the art nanomedicines GMP facility in Oss, NL, where we develop and manufacture complex drug formulations requiring advanced nanoparticles, whether lipid, polymeric or metal platforms. We're also expanding our bioanalytical capabilities significantly, including a brand new, 3,500 sq ft GLP lab in Oss, NL and additional investments in our Assen, NL Center of Excellence for Mass Spectrometry and Immunochemistry, including new capacity and automation technologies. And we’re continuing to further invest in our aseptic fill-finish GMP capabilities in Ghent, Belgium.
All these advancements position us to support more sophisticated drug development requirements for advanced therapies as well as increase capacity to provide shorter timelines and more flexibility to our customers. Additionally, we’re showcasing enhancements in handling highly potent APIs (HPAPI) both in our Drug Substance and Drug Product offerings, a growing area of need in oncology and other specialized therapeutic areas.
What are you hoping to achieve from the event?
Our participation at CPHI Milan 2024 is driven by a desire to engage with both existing and prospective clients, as well as explore new scientific and technical collaborations within the industry. With expanded bioanalytical capabilities and a brand-new nanomedicines GMP facility, we’re looking to showcase how these services can streamline drug development for our partners. We also aim to gain insights into market trends and regulatory shifts, ensuring our investments align with industry demands. The event offers an ideal platform to discuss how our integrated CDMO model can address clients' needs, particularly as we continue growing in key regions like the US or Asia.
Can you discuss any plans for expansion or market growth in the pipeline?
Ardena is in the midst of significant growth, both in terms of service capacity and geographical presence. Domestically in Europe, we just opened our new nanomedicines GMP facility in Oss, NL, and we are enhancing our bioanalytical services, with a new lab in Oss, NL and continued expansion of our Assen, NL Center of Excellence. Internationally, we are focusing on expanding our footprint in the US and in Asia. These strategic expansions are part of our long-term plans to better serve both established pharma companies and emerging biotechs with a full suite of development services.
What sets your company apart from competitors in the pharmaceutical industry, and what value do you offer to your customers?
Ardena’s differentiation lies in our ability to seamlessly integrate drug development services across drug substance, drug product, bioanalysis, and CMC regulatory support. This allows us to offer a truly end-to-end solution tailored to the unique needs of each client, whether they are navigating early-stage research or preparing for clinical trials. Our investments in nanomedicines, enhanced bioanalytical capabilities, and international expansion reflect our commitment to staying ahead of market demands. Our flexible, phase-appropriate development approach, combined with in-depth regulatory expertise, ensures that clients can confidently navigate each step of the drug development process, ultimately reducing risks and accelerating time to clinic and market.
